Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 9024 results

  1. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  3. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    In development Reference number: GID-TA11655 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Suspected cancer (QS124)

    April 2026: We have withdrawn this quality standard following the launch of the updated NICE guideline on suspected cancer: recognition and referral. An updated NICE quality standard for suspected cancer is being developed.  For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard

  5. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE HealthTech guidance 733.

    Withdrawn guidance

  6. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

    Technology appraisal guidance
    Discontinued

  8. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    Discontinued Reference number: GID-TA11228

    Technology appraisal guidance
    Discontinued

  9. Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]

    In development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued Reference number: GID-TA10148

    Technology appraisal guidance
    Discontinued

  11. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146).

    Withdrawn guidance

  12. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148).

    Withdrawn guidance

  13. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

    Medical technologies guidance
    In development

  14. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

    Health technology evaluations
    In development

  15. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development